86 related articles for article (PubMed ID: 7119791)
1. Cyclocreatine phosphate, an analogue of creatine phosphate, does not improve hypoxic tolerance in mice.
Artru AA; Michenfelder JD
J Neurochem; 1982 Oct; 39(4):1198-200. PubMed ID: 7119791
[TBL] [Abstract][Full Text] [Related]
2. Enhanced ability of skeletal muscle containing cyclocreatine phosphate to sustain ATP levels during ischemia following beta-adrenergic stimulation.
Turner DM; Walker JB
J Biol Chem; 1987 May; 262(14):6605-9. PubMed ID: 3571272
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of analgo of phosphocreatine in muscle of chicks fed 1-carboxymethyl-2-iminoimidazolidine (cyclocreatine).
Griffiths GR; Walker JB
J Biol Chem; 1976 Apr; 251(7):2049-54. PubMed ID: 1270421
[TBL] [Abstract][Full Text] [Related]
4. Utilization of cyclocreatine phosphate, and analogue of creatine phosphate, by mouse brain during ischemia and its sparing action on brain energy reserves.
Woznicki DT; Walker JB
J Neurochem; 1980 May; 34(5):1247-53. PubMed ID: 7373304
[No Abstract] [Full Text] [Related]
5. Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency.
Kurosawa Y; Degrauw TJ; Lindquist DM; Blanco VM; Pyne-Geithman GJ; Daikoku T; Chambers JB; Benoit SC; Clark JF
J Clin Invest; 2012 Aug; 122(8):2837-46. PubMed ID: 22751104
[TBL] [Abstract][Full Text] [Related]
6. Utilization of the synthetic phosphagen cyclocreatine phosphate by a simple brain model during stimulation by neuroexcitatory amino acids.
Woznicki DT; Walker JB
J Neurochem; 1988 May; 50(5):1640-7. PubMed ID: 2896231
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and accumulation of an extremely stable high-energy phosphate compound by muscle, heart, and brain of animals fed the creatine analog, 1-carboxyethyl-2-iminoimidazolidine (homocyclocreatine).
Roberts JJ; Walker JB
Arch Biochem Biophys; 1983 Feb; 220(2):563-71. PubMed ID: 6824340
[TBL] [Abstract][Full Text] [Related]
8. The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors.
Schimmel L; Khandekar VS; Martin KJ; Riera T; Honan C; Shaw DG; Kaddurah-Daouk R
Anticancer Res; 1996; 16(1):375-80. PubMed ID: 8615639
[TBL] [Abstract][Full Text] [Related]
9. Critical role of phosphagens in the energy cascade of cutaneous ischemia and protective action of phosphocreatine analogues in skin flap survival.
Cuono CB; Marquetand R; Klein MB; Armitage I
Plast Reconstr Surg; 1998 May; 101(6):1597-603. PubMed ID: 9583491
[TBL] [Abstract][Full Text] [Related]
10. Energy metabolism of skeletal muscle containing cyclocreatine phosphate. Delay in onset of rigor mortis and decreased glycogenolysis in response to ischemia or epinephrine.
Annesley TM; Walker JB
J Biol Chem; 1980 May; 255(9):3924-30. PubMed ID: 7372660
[No Abstract] [Full Text] [Related]
11. Electrophysiology and biochemical analysis of cyclocreatine uptake and effect in hippocampal slices.
Enrico A; Patrizia G; Luisa P; Alessandro P; Gianluigi L; Carlo G; Maurizio B
J Integr Neurosci; 2013 Jun; 12(2):285-97. PubMed ID: 23869866
[TBL] [Abstract][Full Text] [Related]
12. Facile High-Performance Liquid Chromatography Mass Spectrometry Method for Analysis of Cyclocreatine and Phosphocyclocreatine in Complex Mixtures of Amino Acids.
Tao D; Leister W; Huang W; Alimardanov A; LeClair CA
J Agric Food Chem; 2019 Jun; 67(25):7190-7196. PubMed ID: 31194545
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells.
Martin KJ; Chen SF; Clark GM; Degen D; Wajima M; Von Hoff DD; Kaddurah-Daouk R
J Natl Cancer Inst; 1994 Apr; 86(8):608-13. PubMed ID: 8145276
[TBL] [Abstract][Full Text] [Related]
14. Phosphocyclocreatine is the dominant form of cyclocreatine in control and creatine transporter deficiency patient fibroblasts.
Gorshkov K; Wang AQ; Sun W; Fisher E; Frigeni M; Singleton M; Thorne N; Class B; Huang W; Longo N; Do MT; Ottinger EA; Xu X; Zheng W
Pharmacol Res Perspect; 2019 Dec; 7(6):e00525. PubMed ID: 31859463
[TBL] [Abstract][Full Text] [Related]
15. Formation and utilization of novel high energy phosphate reservoirs in Ehrlich ascites tumor cells. Cyclocreatine-3-P and creatine-P.
Annesley TM; Walker JB
J Biol Chem; 1978 Nov; 253(22):8120-5. PubMed ID: 568626
[No Abstract] [Full Text] [Related]
16. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors.
Lillie JW; O'Keefe M; Valinski H; Hamlin HA; Varban ML; Kaddurah-Daouk R
Cancer Res; 1993 Jul; 53(13):3172-8. PubMed ID: 8319226
[TBL] [Abstract][Full Text] [Related]
17. Cyclocreatine phosphate as a substitute for creatine phosphate in vertebrate tissues. Energistic considerations.
Annesley TM; Walker JB
Biochem Biophys Res Commun; 1977 Jan; 74(1):185-90. PubMed ID: 836276
[No Abstract] [Full Text] [Related]
18. Relative abilities of phosphagens with different thermodynamic or kinetic properties to help sustain ATP and total adenylate pools in heart during ischemia.
Turner DM; Walker JB
Arch Biochem Biophys; 1985 May; 238(2):642-51. PubMed ID: 3994395
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of rate of tumor growth by creatine and cyclocreatine.
Miller EE; Evans AE; Cohn M
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3304-8. PubMed ID: 8475072
[TBL] [Abstract][Full Text] [Related]
20. Creatine and cyclocreatine effects on ischemic myocardium: 31P nuclear magnetic resonance evaluation of intact heart.
Osbakken M; Ito K; Zhang D; Ponomarenko I; Ivanics T; Jahngen EG; Cohn M
Cardiology; 1992; 80(3-4):184-95. PubMed ID: 1511465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]